- Home
- DSGX vs JAZZ Comparison
DSGX vs JAZZ Comparison
Compare DSGX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGX
- JAZZ
- Stock Information
- Founded
- DSGX 1981
- JAZZ 2003
- Country
- DSGX Canada
- JAZZ Ireland
- Employees
- DSGX N/A
- JAZZ N/A
- Industry
- DSGX Computer Software: Prepackaged Software
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DSGX Technology
- JAZZ Health Care
- Exchange
- DSGX Nasdaq
- JAZZ Nasdaq
- Market Cap
- DSGX 9.8B
- JAZZ 8.5B
- IPO Year
- DSGX 1999
- JAZZ 2007
- Fundamental
- Price
- DSGX $100.42
- JAZZ $138.81
- Analyst Decision
- DSGX Buy
- JAZZ Strong Buy
- Analyst Count
- DSGX 12
- JAZZ 15
- Target Price
- DSGX $117.25
- JAZZ $189.73
- AVG Volume (30 Days)
- DSGX 364.7K
- JAZZ 1.1M
- Earning Date
- DSGX 03-05-2025
- JAZZ 04-30-2025
- Dividend Yield
- DSGX N/A
- JAZZ N/A
- EPS Growth
- DSGX 22.39
- JAZZ 41.75
- EPS
- DSGX 1.64
- JAZZ 8.65
- Revenue
- DSGX $651,000,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- DSGX $13.20
- JAZZ $7.30
- Revenue Next Year
- DSGX $12.03
- JAZZ $4.01
- P/E Ratio
- DSGX $59.88
- JAZZ $16.05
- Revenue Growth
- DSGX 13.63
- JAZZ 6.12
- 52 Week Low
- DSGX $87.20
- JAZZ $99.06
- 52 Week High
- DSGX $124.31
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DSGX 27.22
- JAZZ 58.98
- Support Level
- DSGX $92.55
- JAZZ $135.36
- Resistance Level
- DSGX $110.99
- JAZZ $142.93
- Average True Range (ATR)
- DSGX 3.36
- JAZZ 4.62
- MACD
- DSGX -1.23
- JAZZ -0.39
- Stochastic Oscillator
- DSGX 32.81
- JAZZ 40.25
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.